AbelsonTaylor Appoints New Marketing Intelligence Leader
The global health and wellness advertising agency promoted Amanda Hartzmark from Director of Business Development and Analysis to Senior Director of Marketing Intelligence. Hartzmark will take charge of efforts to uncover new market opportunities and help clients achieve maximum growth. She has already proved herself to be an analytical tech guru, having recently led two large-scale AbelsonTaylor surveys examining how COVID-19 is affecting physician relationships with their patients and the pharmaceutical industry.
“Amanda’s vision for the future of pharma marketing and her leadership on our recent physician surveys are providing our clients with actionable insight and value,”
Christopher Dimmock, Senior Vice President, Integrated Strategy, stated. “She has the research and analytics expertise to guide our organization forward and to clearly identify key challenges and areas of opportunity.” With over 16 years of experience, Hartzmark is also trusted to connect leading indicators from engagement channels to key lagging metrics such as sales and share measures that connect optimal marketing efforts to business results.
Dr. Noonberg To Spearhead Maze Therapeutics’ Pipeline
The company focused on translating genetic insights into new medicines announced the appointment of Sarah Noonberg, MD, PhD, as Chief Medical Officer. With a track record in global clinical development and corporate strategy, Dr. Noonberg was brought on board as Maze works to advance its pipeline for a broad range of diseases. Previously, she was Head of Global Clinical Development at BioMarin Pharmaceutical, Inc., where she advanced a broad portfolio including Brineura for CLN2 disease and Palynziq for phenylketonuria.
“We are thrilled to welcome Sarah to the Maze team,” said Jason Coloma, PhD, CEO of Maze. “We have been working hard to build an exciting pipeline of potential therapeutics based on targets generated through our platform, and Sarah’s broad experience leading programs from translational research through commercialization for both rare and common diseases will be instrumental.”
The precision genetic medicine company focused on preventing hearing loss appoints Alan Smith, PhD, as Chief Technology Officer. Dr. Smith boasts 30 years of experience in research and development, manufacturing, and quality in the areas of cell and gene therapies. He has contributed to more than 25 FDA regulatory submissions for cell therapy products and devices throughout his career.
Caris Life Sciences
The precision medicine innovator hires Brian Lamon, PhD, as the new Chief Business Officer, Head of BioPharma Business Development. Dr. Lamon will be responsible for developing the partnering and business development strategy for the company and translating that strategy into actionable and achievable goals. He brings 15 years of experience to Caris, most recently serving as VP, Development Lead, Genitourinary Malignancies, Oncology Development at Bristol Myers Squibb.
Expanding its data science division, the digital agency hires Monika Klimek to manage the unit as VP of Data Science. Klimek will lead her team to engineer transformative experiences and deliver brand growth. They will apply the latest technologies, such as smart tagging, data enrichment, and predictive algorithms, to build brand-supported tactics that can be used across all channels and maximize ROI.
Facebook is promoting Alex Schultz to Chief Marketing Officer from VP of Growth and Analytics. Schultz has spent much of the past four years working on the network’s brand safety issues through improving its community standards and independent code of conduct report with the European Commission.
The full-service health agency has appointed industry veteran, Tony Jerig, as its first Head of Information Technology. With 30 years of industry experience, Jerig is expected to ensure seamless integration as Fingerpaint continues to expand its capabilities through organic growth, new offices, and acquisitions.
The leading data-driven performance marketing company appoints Carla Newell to its Board of Directors. Newell has had 30 years of success facilitating growth in the technology, digital business, and life sciences arenas. She currently serves as Chief Legal and Risk Officer and Head of Health Business Development for Ancestry.
The creative health agency appointed Jim Joseph as President, North America. He will be responsible for overseeing all North American advertising and promotion agencies in the U.S. and Canada, as well as build and expand the North American growth team. An award-winning marketer, Joseph is known for leading and managing global brands and agencies for sustained growth and innovation.
Peter A. Schwartzman is joining the newly formed Capital, Strategy, and Transactions (CST) Group at the endocrine-focused therapeutics company as Vice President. Schwartzman and his group are responsible for the analysis and due diligence required for all business development activities and will also build the financial model framework Radius uses to assess current and future performance.
Jose “Pepe” Carmona is the new Chief Financial Officer of the biopharma company genetically engineering red blood cells to create cellular medicines. Carmona has over 20 years of experience in finance and operations and a track record of financing clinical-stage and commercial biotech companies, previously serving as CFO of Radius Health.
The healthcare communications company appointed Bryce McMurray to the newly created VP Medical Communications position. McMurray will help broaden the company’s customized and integrated services for the wider medical communications market while driving synergies between the strategic medical communications and medical education product portfolios designed to suit the needs of global pharma.
Supernus Pharmaceuticals, Inc.
James Kelly was named Chief Financial Officer in order to develop financial operations and strategy to effectively support growth for the pharma company focused on central nervous system disease therapies. Kelly was most recently CFO of Vanda Pharmaceuticals, gaining experience in publicly traded companies, as well as the development and commercialization of pharmaceutical products.
Vineti, a cloud-based platform to expand patient access to life-saving cell and gene therapies, taps Joe DePinto as its new Chief Commercial Officer. DePinto’s commercialization expertise is expected to lend to the company’s goal of industrializing personalized therapeutics, such as CAR-T cell therapies. Previously, he was a key leader at Cardinal Health, spearheading operational expansion.